PTEN and neoplasm: A combination of genetic and chemical genetic experiments demonstrate that these defects are due to the loss of the lipid phosphatase activity of PTEN and to the activation of 3-phosphoinositide-dependent protein kinase-1 (PDPK1 (PDK1)), but do not depend on the AKT-mTOR tumor suppressor pathway.